CBG-002 / Carbiogene Therap - LARVOL DELTA

A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. (PubMed, PLoS One) - P2 | "In cutaneous melanoma patients, the presence of lymph node or in transit metastasis can be associated with poor survival. The trial is supported by Sydney Cancer Partners with funding from Cancer Institute NSW (Grant ID 2021/CBG0002). The sponsors are Sydney Local Health District and Melanoma Institute Australia."

Clinical protocol • IO biomarker • Journal • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Carbiogene Therapeutics Co. Ltd.

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial. (PubMed, Cancer Immunol Res) - P1 | "The median OS was not reached, and the median PFS was 8.5 (2.7-22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T therapy, demonstrated safety and clinical efficacy in patients with RRMM."

CAR T-Cell Therapy • Journal • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • CD27

Biomarkers to predict chemotherapy response in low-grade serous ovarian carcinoma (ESMO-GC 2024) - "Dr Seema Kumari was the recipient of a PhD Scholarship from Sydney Cancer Partners with funding from Cancer Institute NSW (2021/CBG0002)...We aimed to identify molecular features predictive of response to docetaxel, paclitaxel and gemcitabine in well-defined LGSC cell line models. Cell viability was assessed following docetaxel, paclitaxel and gemcitabine exposure in eight LGSC lines (CellTiter 96™ MTS Assay, Promega)... Our pre-clinical data suggests that non-platinum chemotherapy may be a viable option in selected LGSC patients. Gene expression profiles associated with response to specific agents were identified. However, these findings need further validation in patient samples."

Biomarker • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Oct 2022 ➔ Oct 2023

CAR T-Cell Therapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University; Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1; N=25; Not yet recruiting; Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology